Roswell Park Center for Immunotherapy

The Roswell Park Center for Immunotherapy (CFI) conducts early entry Phase I/II cancer immunotherapy clinical trials focusing on high priority agents and combinations of immunotherapy modalities. The CFI's primary goal is to address the challenge of developing effective immunologic therapies for human cancers.

Established in 2009, the Center tests strategies such as cancer vaccines, antibody therapy, cellular therapy and immune response modifiers. Because of the recognition that several variables need to be brought together and tested individually in the construction of successful immunotherapies, the CFI seeks to test the variables in parallel, rather than sequential, clinical trials.

Executive Director
Kunle Odunsi

Kunle Odunsi, MD, PhD, FRCOG, FACOG
Deputy Director
Chair, Department of Gynecologic Oncology
The M. Steven Piver Professor of Gynecologic Oncology
Executive Director, Center for Immunotherapy
Co-Leader, Tumor Immunology and Immunotherapy Program

Read a message from Dr. Odunsi

 

Contact

Ayo Odunsi, CPA, MBA
Administrator
Tel:  716-845-3215 or 716-845-1300, ext. 6482
Fax: 716-845-1595
ayotunde.odunsi@roswellpark.org

Margaret Ryszka
Principal Secretary
Tel:  716-845-2375
Fax: 716-845-1595
margaret.ryszka@roswellpark.org